Old Mission Capital’s Innate Pharma IPHA Stock Holding History

Old Mission Capital’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,431	Closed	-$49.8K	–	1184
2025 Q4	$49.8K	Buy	+28,431	New	+$54.9K	﹤0.01%	983
2020 Q1	–	Sell	-13,038	Closed	-$84K	–	438
2019 Q4	$84K	Buy	+13,038	New	+$80.1K	0.01%	299

Other funds holding IPHA

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Old Mission Capital's IPHA Position: Q1 2026 in Review

Old Mission Capital sold out of Innate Pharma (IPHA) in Q1 2026, closing a stake of 28,431 shares — an estimated $49.8K sold.

Old Mission Capital first reported a position in IPHA in Q4 2019 and held it in 2 quarters. The position peaked at $84K in Q4 2019. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

Old Mission Capital reported no remaining Innate Pharma position as of Q1 2026 after selling out during the quarter.
Old Mission Capital sold 28,431 Innate Pharma shares in Q1 2026, an estimated $49.8K.
Old Mission Capital first reported a position in Innate Pharma in Q4 2019 and held it in 2 quarters.
Old Mission Capital's Innate Pharma position peaked at $84K in Q4 2019.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on Old Mission Capital's 13F filing for Q1 2026, filed 15 May 2026.